Detalhe da pesquisa
1.
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.
Nat Immunol
; 21(8): 914-926, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32424363
2.
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
Nature
; 629(8010): 201-210, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38600376
3.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(14): 1265-1276, 2024 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38598794
4.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(2): 118-131, 2024 Jan 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38197815
5.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
Lancet
; 401(10378): 733-746, 2023 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36764316
6.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 42(1): 145-159, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38324085
7.
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
J Pathol
; 259(1): 81-92, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36287571
8.
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Future Oncol
; 20(7): 361-371, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37767626
9.
Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
Intern Med J
; 2024 Feb 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38369719
10.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
N Engl J Med
; 383(21): 2018-2029, 2020 11 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33207094
11.
Comprehensive profiling identifies tumour and immune microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma.
Br J Dermatol
; 189(5): 588-602, 2023 10 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37470440
12.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37306090
13.
14.
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cochrane Database Syst Rev
; 1: CD013453, 2022 Jan 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34994987
15.
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Future Oncol
; 17(34): 4649-4656, 2021 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34585621
16.
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future Oncol
; 17(7): 763-773, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33150799
17.
IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.
Mol Ther
; 28(11): 2379-2393, 2020 11 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32735774
18.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 20(12): 1691-1701, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31669155
19.
Clinical Management of Adverse Events Associated with Lorlatinib.
Oncologist
; 24(8): 1103-1110, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30890623
20.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30413378